Trial reportIndian journal of pediatrics2026
Randomised Controlled Trial Comparing Single Maintenance and Reliever Therapy (SMART) with Inhaled Budesonide-Formoterol Combination, Versus Conventional Budesonide and Additional As-Needed Levo-Salbutamol, in Children with Persistent Bronchial Asthma.
Trial report in Indian journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Randomised Controlled Trial Comparing Single Maintenance and Reliever Therapy (SMART) with Inhaled Budesonide-Formoterol Combination, Versus Conventional Budesonide and Additional As-Needed Levo-Salbutamol, in Children with Persistent Bronchial Asthma: Author's Reply.Indian journal of pediatrics · 2026Article
- Randomised Controlled Trial Comparing Single Maintenance and Reliever Therapy (SMART) with Inhaled Budesonide-Formoterol Combination, Versus Conventional Budesonide and Additional As-Needed Levo-Salbutamol, in Children with Persistent Bronchial Asthma: Correspondence.Indian journal of pediatrics · 2026Article
- MART Therapy in Children of 6-11 Years of Age.Indian journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the efficacy, safety and cost of Single Maintenance and Reliever Therapy (SMART) with low dose inhaled budesonide-formoterol combination vs. conventional budesonide plus as-needed levo-salbutamol, in 6-11-y-old children with asthma.
methodsIn this randomised controlled trial (RCT), 84 children (6-11 y) with treatment-naïve asthma were randomised to either SMART with inhaled budesonide-formoterol combination, or budesonide plus as-needed levo-salbutamol. Peak expiratory flow (PEF), asthma symptom score, number of rescue doses, exacerbations, adherence, inhalation technique, adverse events and cost were recorded over the first 12 wk of follow-up.
resultsBaseline PEF, asthma symptom score, and other characteristics were comparable. At the end of 12 wk, the median (IQR) improvement in PEF was 16% (10, 20) vs. 11% (8.5, 15.5), p = 0.01. The median (IQR) weekly asthma symptom score was 3 (2, 4.5) vs. 4 (3, 7), p = 0.02. The median (IQR) number of rescue doses were 0 (0, 0) vs. 4 (3, 6), p = 0.02. Only 9/37 (24.3%) vs. 16/37 (43.2%) children had exacerbations, p = 0.05. There were no adverse effects considered significant in either group. The total cost of treatment was lower with SMART.
conclusionsSMART showed greater short-term efficacy and was less expensive compared to conventional therapy in 6-11 y-old asthmatic children, with no additional safety concerns.
Indexed as
Identifiers
41405824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.